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ABSTRAK
Tujuan: mengevaluasi efek N-asetilsistein (NAS) oral terhadap kadar petanda inflamasi pada pasien 
Continuous Ambulatory Peritoneal Dialysis (CAPD). Metode: 32 pasien  yang menjalani regular CAPD, dibagi 
menjadi dua kelompok masing-masing 16 pasien. Sistem imun ditentukan dari rerata kadar Prokalsitonin, IL-6, 
IL-1, C3, sICAM, hsCRP, dan TNF-a sebelum dan sesudah pemberian NAS 2x600 mg/hari selama 8 minggu. 
T-test digunakan untuk membedakan rerata kelompok NAS dengan kontrol, Semua uji statistik menggunakan 
SPSS software (SPSS Ver 16.0). Hasil: pemberian NAS, secara bermakna menurunkan kadar petanda inflamasi 
dibandingkan kelompok kontrol PCT (-0,38±0,57 vs 0,09±0,14; p=0,004), IL-6 (-1,94±3,03 vs 1,19±1,99; 
p=0,002), IL-1 (-0,14±0,21 vs 0,01±0,04; p=0,010), C3 (-7,40±12,04 vs 4,60±8,12; p=0,002), sICAM 
(-80,59±29,18 vs -35,02±46,99; p=0,007), hsCRP (-1,50±1,32 vs 0,81±1,17; p<0.001) and TNF-a (-0,73±0,47 
vs 0,14±0,74; p<0.001). Kesimpulan: pemberian NAS peroral mampu menurunkan kadar PCT, IL-6, IL-1, C3, 
sICAM, hsCRP, dan TNF-a pasien CAPD.
Kata kunci: CAPD, prokalsitonin, IL-6, IL-1, C3, sICAM, hsCRP, TNF-a, N-asetilsistein.
ABSTRACT
Aim: to determine the effect of oral N-acetylcysteine (NAC) on plasma levels of inflammatory markers in 
Continuous Ambulatory Peritoneal Dialysis (CAPD) patients. Methods: we performed a placebo-controlled 
study over 8 weeks in 32 patients on regular CAPD. The patients were divided into 2 groups of 16 patients 
matched for age and gender. The first group was given NAC 2x600 mg/day for 8 weeks and inflammatory 
parameter was compared with control group. The immune system is determined from the average levels of 
Procalcitonin, IL-6, IL-1, C3, SICAM, hsCRP, and TNF-a  before and after treatment with NAC. Student t-test 
was performed to compare the means between NAC receiving and control groups. All statistics were done using 
SPSS software (SPSS Ver 16.0). Results: administration of NAC, significantly diminished PCT (-0.38±0.57 vs 
0.09±0.14; p=0.004), IL-6 (-1.94±3.03 vs 1.19±1.99; p=0.002), IL-1 (-0.14±0.21 vs 0.01±0.04; p=0.010), C3 
(-7.40±12.04 vs 4.60±8.12; p=0.002), sICAM (-80.59±29.18 vs -35.02±46.99; p=0.007), hsCRP (-1.50±1.32 
vs 0.81±1.17; p<0.001) and TNF-a (-0.73±0.47 vs 0.14±0.74; p<0.001) levels compared control to group. 
Conclusion: short-term oral NAC treatment resulted in reduction of circulating PCT, IL-6, IL-1, C3, sICAM, 
hsCRP, and TNF-a in CAPD patients. 
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INTRODUCTION
Cardiovascular diseases are important main 
causes of mortality and morbidity in chronic 
kidney disease (CKD).1,2 Non classical factors 
such as inflammation and oxidative stress, played 
an important role.3 Patients on dialysis endure 
persistent oxidative and inflammation stresses. 
The properties of Reactive Oxygen Species 
(ROS) that impaired and destroy cells contribute 
to atherogenesis.4 
Patients with CKD, show an increase on 
blood uremic level that will amplify pro-oxidant 
and pro-inflammation responses which will lead 
to progressivity of atherosclerosis processes and 
the rise of mortality number.5
Epidemiological studies have reported the 
association between circulating inflammation 
marker (includes hsCRP, IL-6 and TNF-a) 
with the risk of chronic diseases.6 Ureum 
decreases cellular immunity, fagocytosis ability 
and antibody production, that will increase 
the risk of infection.7 C3 plays a central role 
in complement system activation through 
clasiccal and alternative pathway, meaning 
that C3 deficiency will lead to the increase of 
the body susceptibility to infection.8 sICAM 
is a biomarker for inflammation processes that 
involves activation or desruction on cells such 
as trombocytes and endothelial cells.9
Antioxidant supplementation is one strategy 
to reduce oxidative stress in CKD patients. 
Low cost, safety, with its aptitude good effects, 
N-acetylcysteine (NAC) becomes a potential 
antioxidant and anti-infllamation drug for 
dialysis patients. NAC is a thiol containing 
subtance with antioxidative properties that 
eradicate free radicals. In its reactive sulfhidril 
form, NAS shows its capability to increase its 
reduction capacity.10 NAC has been used as 
mucolytic in chronic bronchitis therapy and 
as antidotes in paracetamol overdose. In vitro 
studies have showed that NAS raise a number 
of T cell functions.4  
In the field of nephrology, NAC has been 
used to prevent contrast induced nephropathy. 
In hemodialysis patients, NAC has been showed 
to markedly reduce cardiovascular events 
(Tepel, 2007). In peritoneal dialysis, studies 
showed that NAC has the antioxidant capacity 
to protect peritoneal membrane and to reduce 
intraperitoneal advanced glyclation end products 
(AGEs) production in the laboratory animals. 
Despite some evidences, the antioxidant and 
antiinflammatory effects of NAC on CAPD 
patients remain unclear. In this study, we would 
like to evaluate, whether NAC’s supplementation 
antioxidant or antiinflammation properties, could 
reduce the level of PCT, IL-6, IL-1, C3, sICAM, 
hsCRP and TNF-a in CAPD subjects.
METHODS
Study, Design, and Participants
This is a prospective randomized control 
trial study, held in nephrology and hypertension 
division in the Moewardi public hospital, 
Surakarta, Indonesia. 
From August to September 2011, we enrolled 
32 consecutive CKD stage V patients that were 
undergoing CAPD therapy for at least 3 months 
to 5 years in the hospiltal’s CAPD unit and 
those who agreed to join the study had to sign 
an informed consent.  
Thirty two eligible patients joined the study, 
were randomly divided into 2 groups, the NAC 
and control groups each consisted of 16 subjects. 
The treatment group received NAC (2x600 mg/
day) for 8 weeks and the other group received 
placebo.
Patients with CKD stage V fulfilling the 
following criteria were recruited:
Those who had renal damage for at least 3 
months with structural or functional impairment, 
with or without decreased glomerular filtration 
rate, with GFR less than 60 ml/minutes/1.73m². 
and with signs of renal impairment, including 
blood and urine marker, or imaging test findings.
Those who had stage V CKD marked by 
GFR of <15 mL/minutes without considering the 
ethiology of the impairment and has undergoing 
at least 3 months of CAPD therapy. 
Before a patient could undergo CAPD therapy, 
he/she must fulfill prerequisite conditions.
Inclusion criteria included patient who had 
been diagnosed with stage V CKD proved by 
renal ultrasonography, blood laboratory and 
urinalysis that are in concordance with K/DOQI 
2002 criteria, 20-59 years of age, underwent 
CAPD for at least 3 months and less than 5 years, 
not suffering from any form of infection, not in 
sepsis, systolic blood pressure more than 100 
mmHg, hemoglobin level more than 6 mg/dL, 
not suffering from heart arrhythmya or chronic 
hepatitis B and C. Exclusion criteria included 
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patients with stage V Diabetic Nephropathy, 
on steroid therapy, malignancy, or obstructive 
uropathy. 
Study Parameters
PCT, IL-6, IL-1, C3, sICAM, hsCRP, and 
TNF-a level were measured from 5 cc venous 
blood sample taken before and after 8 weeks 
of NAC therapy. ELISA method was used for 
the blood examination conducted by PRODIA 
laboratory.
Statistical Analysis
Data (before and after 8 weeks of oral NAC 
supplementation) were analyzed using unpaired 
t-test. All statistical analyses were done by 
software SPSS 16 for windows. 
RESULTS
The basal clinical characteristics of the two 
groups of patients are given in Table 1. Age, 
gender, hemoglobin, ureum, creatinin, kalium 
and albumin status before the intervention did 
not differ significantly between the groups.
This study shows that 8 weeks of oral NAC 
supplementation, significantly reduced the 
level of PCT (p=0.004), IL-6 (p=0.002), IL-1 
(p=0.010), C3 (p=0.002), sICAM (p=0.007), 
hsCRP (p<0.001) and TNF-a (p<0.001) compare 
to the control group. 
Table 1. Baseline characteristics of patients receiving 
N-acetylcysteine (NAC) or placebo
NAC group Placebo group
Age (years) 45,79+7.59 42.54+6.79
Male gender (%) 64,28 69,23
Hemoglobin (g/dL) 10.44+2.01 9.49+2.44
Serum Ureum (mg/dL) 128.6+63.9 121.1+39.5
Serum creatinin (mg/dL) 15.01+4.64 21.71+29.73
Serum Kalium (mEq/L) 3.49+0.79 3.40+1.05
Serum albumin (g/dL) 3.33+0.51 3.25+0.59
DISCUSSION
Chronic kidney disease patients are 10 to 
20 times more prone to cardiovascular diseases 
compared to others in general population. 
Endothelial dysfunction plays a major role in 
the progressivity of atherosclerosis process. 
CKD patients shows endothelial depended 
Table 2. Difference in cytokine levels (before and after 
8 weeks of NAC therapy) in group treated with NAC and 
in control group. Values are presented as mean+SD
Variables NAC Control p value
PCT -0.38±0.57 0.09±0.14 0.004
TNF -0.73±0.47 0.14±0.74 <0.001
hsCRP -1.50±1.32 0.81±1.17 <0.001
C3 -7.40±12.04 4.60±8.12 0.002
sICAM -80.59±29.18 -35.02±46.99 0.007
IL-6 -1.94±3.03 1.19±1.99 0.002
IL-1 -0.14±0.21 0.01±0.04 0.010
vasodilatation impairment, increase level 
of endothelial dysfunction marker, and the 
escalation of oxidative stress.
Endhotelial damage induced by uremic 
environment indicates the involvement of 
specific uremic factor. A number of uremic toxins 
such as asymmetric dimethylarginine (ADMA), 
homocystein, advanced glycation end products 
(AGE), p-cresyl sulfate and indoxyl sulfate, 
that most of which protein bounded, expresses 
toxicity to endhotelial cells. The amount of 
those toxin that could be reduced through 
hemodialysis is negligible or not at all. The toxin 
will then cause endhotelial toxicity by a number 
of mechanism which will lead to augmentation 
of pro-oxidant and pro-inflammation responses 
and also impairment in endothelial repairment.12 
Chronic Kidney disease patients show an 
increase of blood uremic level. Uremic toxin 
such as guanidin, AGE, p-cresyl sulfate, platelet 
diadenosine polyphosphates, and indoxyl sulfate 
causes vascular dysfunction through (i) the 
increase of atherosclerosis process, (ii) uremia 
which involves ADMA, AGE, and oxidative stress 
will stiffen the artery and will cause left ventricle 
hypertrophy and decrease coronary perfussion, 
(iii) vascular calsification and, (iv) abnormality 
in the vascular repairment ability and neointimal 
hyperplasia will intensify vascular narrowing. 
Atherosclerosis and cardiovascular diseases 
are the most important cause for CKD patients; 
morbidity and mortality.13 There is correlation 
between uremic toxin and cardiovascular death.14
The study result shows that 2X600 mg of 
NAC for 8 weeks significantly downregulates the 
level of inflammation marker such as PCT, IL-
6, IL-1, C3, sICAM, hsCRP and TNF-a. This is 
probably due to the ability of NAC as antioxidant 
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to prevent the activation of NF-kB induction 
and inhibits induction of expression and also 
secretion of proinflammatory cytokines.15 NAC 
also prevented endhotelial mollecular adhesion 
expression and damage due to peroxinitrit free 
radicals.16 In the cytoplasm, NF-kB bounded 
with IkB protein, but in the event of oxidative 
stress, the bound break apart causing further 
degradation and the release of IkB. NAC therapy 
will block the TNF-a and NF-KB activation. 
The antioxidant properties of NAC also induced 
structural modification which will reduce the 
TNF-a affinity receptor.17  
Reduction of IL-6 by NAC is in concordance 
with the study by Nascimento et al (2010).18 NAC 
also affectively decreases TNF-a level,19 which 
differ from Nascimento’s study,18 and shows that 
there’s no significant effect on TNF-a level in 
patients on peritoneal dialysis. IL-6 and TNF-a 
will stimulate the bone marrow to produce more 
leucocytes. High level of leucocytes will increase 
the number of PMN and monocytes. Neutrophyl 
chemotacting factor properties of IL-8 will 
in turn pull the circulating PMN closer to the 
endhotelial surface. Number of studies have 
showed that sICAM production has an important 
role in arterial plaque process. 
The result of a study made by Bambang 
(2011),19 shows that NAC supplementation 
2X600mg per day for 8 weeks will lower 
IL-6, serum TNF-a and leucocyte count 
significantly compare to that of control. This 
will further support the role of antioxidant and/
or antiinfllamation in preventing coronary heart 
disease and overall reducing the cardiovascular 
events in patients with CKD.20
N-acetylcysteine use rationally in patients 
with CKD, based on its biological activity 
being capable of reducing oxidative stress 
and inflamation. Fact has proved that thiol 
in NAC will inhibit the production pro-
inflammation mediators and stimulates GSH 
celular system.4 NAC and its precursor, cystein, 
work as precursor in GSH biosynthesis, which 
is important as intracellular and extracellular 
antioxidant.21 Thaha et al (2008), reported that 
NAC administered intravenously during dialysis 
could reduce ADMA blood concentration, which 
is a strong predictor for cardiaovascular death 
on dialysis.22 High level of uremic toxemia on 
CKD will impair eritropoetin process as well. 
It will increase the destruction of erythrocytes 
membrane leading to anemia in CKD patients. 
N-acetylcysteine supplementation shows 
the capability of inhibiting cytokines and pro-
inflammatory biomarker such as IL-6, TNF-α,19,23 
PCT,23 hsCRP, IL-1, C3 and sICAM. This in 
turn, will prevent erythrocytes destruction. 
Proinflammatory cytokines will induce ROS 
(reactive oxygen species) which will lead to 
impairment of eritropoetic receptor. In the study 
by Bambang (2011), NAC therapy, although 
not statisically significant, shows the increase 
of hemoglobin. This probably due to the fact 
that eritropoetic process needed 120 days (4 
week more or less), while the research duration 
conducted in only 8 weeks (56 days).23
Chronic kidney disease marked by a 
progressive retention of a number of substance 
which plays a major role in cardiovascular 
damage. Cardiovascular damage is the main 
etiology of mortality in CKD. During the last 
year, especially protein bounded substances 
(eg. indoxylsulfate and p-cresylsulfate) and/
or medium molecules (eg. AGE, sitokin dan 
polifosfat dinukleosid) have been identified as 
the primary toxin that involves in the vascular 
lesion processes affecting endothelial cell 
functions, leucocytes, trombocytes and/or 
vascular smooth muscle cell in people with CKD.
Many of these dissolved substances could 
not be filtered by common dialysis strategy. 
Eradication of the protein bound dissolved 
substances are still limited due to only the free 
fraction of the dissolved substance are filtered 
by diffusion, while the eradication of the bigger 
medium molecules (most are larger peptide 
substance) could be used by increasing the 
dializer pores diameter and using convective 
strategy. 
Also, the new threpeutic strategy for specific 
molecules elimination (eg. Adsorbtion) and/
or specific effect neutralization of a substance 
through pharmacological intervention. All of 
which has with the aim of getting better result 
for people with CKD. 
CONCLUSION 
Oral NAC supplementation 2X600 mg 
perday for eight weeks, could significantly 
lower PCT, IL-6, IL-1, C3, sICAM, hsCRP dan 
TNF-a serum level. This result shows NAC 
administration could be use as a strategy to 
reduce inflammatory reaction in CAPD patients.
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